adp 2.0×10-5 m Search Results


adp (2.5, 5, and 10 μm)  (Bio/Data Inc)
90
Bio/Data Inc adp (2.5, 5, and 10 μm)
<t>Platelet</t> aggregation assay shows a correlation between hyperactivity and malignancy. (A) The mean level of platelet aggregation is significantly higher in patients with invasive ovarian cancer compared with control subjects (Student’s t test, n = 23). In comparison, there is no significant difference in maximal aggregation between the two groups. (B) There are significantly more patients with invasive ovarian cancer with hyperreactive platelets (black bar vs. normal platelets indicated by white bar), as defined by aggregation at 2.5 μM <t>ADP</t> (χ2 test, P = 0.018), but not at 5 and 10 μM of ADP compared with control subjects. CTR, control group; MT, metastatic tumor.
Adp (2.5, 5, And 10 μm), supplied by Bio/Data Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adp+2%2E0%C3%9710-5+m/adp+2+0%C3%9710+5+m/pmc04655568-319-6-23
Average 90 stars, based on 1 article reviews
adp (2.5, 5, and 10 μm) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Platelet aggregation assay shows a correlation between hyperactivity and malignancy. (A) The mean level of platelet aggregation is significantly higher in patients with invasive ovarian cancer compared with control subjects (Student’s t test, n = 23). In comparison, there is no significant difference in maximal aggregation between the two groups. (B) There are significantly more patients with invasive ovarian cancer with hyperreactive platelets (black bar vs. normal platelets indicated by white bar), as defined by aggregation at 2.5 μM ADP (χ2 test, P = 0.018), but not at 5 and 10 μM of ADP compared with control subjects. CTR, control group; MT, metastatic tumor.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer

doi: 10.1073/pnas.1518628112

Figure Lengend Snippet: Platelet aggregation assay shows a correlation between hyperactivity and malignancy. (A) The mean level of platelet aggregation is significantly higher in patients with invasive ovarian cancer compared with control subjects (Student’s t test, n = 23). In comparison, there is no significant difference in maximal aggregation between the two groups. (B) There are significantly more patients with invasive ovarian cancer with hyperreactive platelets (black bar vs. normal platelets indicated by white bar), as defined by aggregation at 2.5 μM ADP (χ2 test, P = 0.018), but not at 5 and 10 μM of ADP compared with control subjects. CTR, control group; MT, metastatic tumor.

Article Snippet: Platelet aggregation was initiated by adding ADP (2.5, 5, and 10 μM) and monitored for 10 min in an eight-channel optical aggregometer (PAP8; Bio/Data Corp.).

Techniques: